Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
Consolidated entity plans to strengthen specialty pharmaceutical offerings, expand manufacturing capacity, and accelerate global market penetration across emerging regions
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
We are building the bridge between complex molecular data and everyday clinical decisions
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
AAV vectors are widely used in gene therapy for their strong therapeutic potential
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Subscribe To Our Newsletter & Stay Updated
